Cargando…
The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration
This study pictures the humoral response of 100 vaccinees to Pfizer/BioNTech COVID-19 vaccine over a year, with particular focus on the influence of a booster shot administered around 10 months after the primary immunization. The response to the vaccination was assessed with Diasorin’s SARS-CoV-2 Tr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962896/ https://www.ncbi.nlm.nih.gov/pubmed/36851157 http://dx.doi.org/10.3390/vaccines11020278 |
_version_ | 1784896116102266880 |
---|---|
author | Swadźba, Jakub Anyszek, Tomasz Panek, Andrzej Chojęta, Agnieszka Piotrowska-Mietelska, Anna Martin, Emilia |
author_facet | Swadźba, Jakub Anyszek, Tomasz Panek, Andrzej Chojęta, Agnieszka Piotrowska-Mietelska, Anna Martin, Emilia |
author_sort | Swadźba, Jakub |
collection | PubMed |
description | This study pictures the humoral response of 100 vaccinees to Pfizer/BioNTech COVID-19 vaccine over a year, with particular focus on the influence of a booster shot administered around 10 months after the primary immunization. The response to the vaccination was assessed with Diasorin’s SARS-CoV-2 TrimericSpike IgG. Abbott’s SARS-CoV-2 Nucleocapsid IgG immunoassay was used to identify SARS-CoV-2 contact, even asymptomatic. In contrast to the gradual decline of the anti-spike IgG between 30 and 240 days after the first dose, an increase was noted between days 240 and 360 in the whole cohort. However, a statistically significant rise was seen only in boosted individuals, and this effect of the booster decreased over time. An increase was also observed in non-boosted but recently infected participants and a decrease was reported in non-boosted, non-infected subjects. These changes were not statistically significant. On day 360, a percentage of new SARS-CoV-2 infections was statistically lower in the boosted vs. non-boosted subgroups. The booster immunization is the most efficient way of stimulating production of anti-spike, potentially neutralizing antibodies. The response is additionally enhanced by the natural contact with the virus. Individuals with a low level of anti-spike antibodies may benefit the most from the booster dose administration. |
format | Online Article Text |
id | pubmed-9962896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99628962023-02-26 The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration Swadźba, Jakub Anyszek, Tomasz Panek, Andrzej Chojęta, Agnieszka Piotrowska-Mietelska, Anna Martin, Emilia Vaccines (Basel) Article This study pictures the humoral response of 100 vaccinees to Pfizer/BioNTech COVID-19 vaccine over a year, with particular focus on the influence of a booster shot administered around 10 months after the primary immunization. The response to the vaccination was assessed with Diasorin’s SARS-CoV-2 TrimericSpike IgG. Abbott’s SARS-CoV-2 Nucleocapsid IgG immunoassay was used to identify SARS-CoV-2 contact, even asymptomatic. In contrast to the gradual decline of the anti-spike IgG between 30 and 240 days after the first dose, an increase was noted between days 240 and 360 in the whole cohort. However, a statistically significant rise was seen only in boosted individuals, and this effect of the booster decreased over time. An increase was also observed in non-boosted but recently infected participants and a decrease was reported in non-boosted, non-infected subjects. These changes were not statistically significant. On day 360, a percentage of new SARS-CoV-2 infections was statistically lower in the boosted vs. non-boosted subgroups. The booster immunization is the most efficient way of stimulating production of anti-spike, potentially neutralizing antibodies. The response is additionally enhanced by the natural contact with the virus. Individuals with a low level of anti-spike antibodies may benefit the most from the booster dose administration. MDPI 2023-01-28 /pmc/articles/PMC9962896/ /pubmed/36851157 http://dx.doi.org/10.3390/vaccines11020278 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Swadźba, Jakub Anyszek, Tomasz Panek, Andrzej Chojęta, Agnieszka Piotrowska-Mietelska, Anna Martin, Emilia The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration |
title | The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration |
title_full | The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration |
title_fullStr | The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration |
title_full_unstemmed | The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration |
title_short | The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration |
title_sort | influence of booster shot and sars-cov-2 infection on the anti-spike antibody concentration one year after the first covid-19 vaccine dose administration |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962896/ https://www.ncbi.nlm.nih.gov/pubmed/36851157 http://dx.doi.org/10.3390/vaccines11020278 |
work_keys_str_mv | AT swadzbajakub theinfluenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT anyszektomasz theinfluenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT panekandrzej theinfluenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT chojetaagnieszka theinfluenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT piotrowskamietelskaanna theinfluenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT martinemilia theinfluenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT swadzbajakub influenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT anyszektomasz influenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT panekandrzej influenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT chojetaagnieszka influenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT piotrowskamietelskaanna influenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration AT martinemilia influenceofboostershotandsarscov2infectionontheantispikeantibodyconcentrationoneyearafterthefirstcovid19vaccinedoseadministration |